You are viewing an expired study

Boston, Massachusetts 02115

  • Waldenstrom's Macroglobulinemia


The purpose of this study is to determine the effects (good or bad) that sildenafil (Viagra) has on patients with slow growing Waldenstrom's macroglobulinemia (WM). Sildenafil blocks the function of several proteins necessary to the survival of certain types of cancer and laboratory tests have shown that it can destroy WM cells.

Study summary:

- Sildenafil will be given orally (at home) at a reduced dose for the first week, then each week for 3 more weeks, the dose will be increased. If the patient has no major side effects, then they will receive the maximal dose for 2 years. If they have major side effects, then the dose of the drug might be lowered or the drug stopped. - Sildenafil will be continued until their is disease progression or serious side effects. - While patients are receiving sildenafil, they will be seen in the clinic on months 1,2,9,15 and 21 for blood tests and a subject questionnaire. They will also be seen on months 3,6,12,18 and 24 for a physical exam, blood test, physical assessment test, CT scans of chest, abdomen and pelvis, and a subject questionnaire. - At the end of the study (month 24) a physical exam, blood tests, physical assessment test and a questionnaire will be conducted. - Follow-up includes clinic visits at month 27,33,39 and 45 for blood tests and a questionnaire as well as visits at month 30,36,42 and 48 for physical exam, blood tests, physical assessment test, bone marrow aspirate and biopsy, CT scans of chest, abdomen and pelvis, and a questionnaire.


Inclusion Criteria: - Clinicopathological diagnosis of Waldenstrom's macroglobulinemia - Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level of > 2 times the upper limit of each institution's normal value - Slowly progressing disease not requiring therapy for at least 3-6 months - ECOG performance status 0,1 or 2 - Total bilirubin < 2 x ULN - SGOT < 3 x ULN - Creatinine < 2 x ULN Exclusion Criteria: - Pregnant or breast-feeding women - Patients who are using organic nitrates or alpha-blockers - Grade III/IV cardiac problems - Resting hypotension (BP < 90/50) or hypertension (BP > 170/110) - Cardiac failure or coronary artery disease causing unstable angina - Evidence of left ventricular outflow obstruction - Impaired autonomic control of blood pressure - Sickle cell anemia - History of priapism - Severe and/or uncontrolled medical disease - Known chronic liver disease - Currently using ritonavir - History of retinal pigmentosa



Primary Contact:

Principal Investigator
Steven P. Treon, MD, MA, PhD
Dana-Farber Cancer Institute

Backup Contact:


Location Contact:

Boston, Massachusetts 02115
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.